Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma
Advanced Science · 2023
DOI: 10.1002/advs.202301975 ↗Kurz gefasst
Fachartikel in der Zeitschrift Advanced Science, 2023. Verfasst von Le Li und 20 weiteren Autor:innen. Beteiligte Einrichtung: Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China. Hauptthemen laut MEDLINE: Carcinoma, Renal Cell, Kidney Neoplasms. Die Arbeit wurde bisher 16-mal zitiert (Crossref) und nennt 46 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: National Natural Science Foundation of China, Medical Science Data Center of Fudan university, Fundamental Research Funds for the Central Universities.
Abstract (Originalsprache)
The Warburg effect‐related metabolic dysfunction of the tricarboxylic acid (TCA) cycle has emerged as a hallmark of various solid tumors, particularly renal cell carcinoma (RCC). RCC is characterized by high immune infiltration and thus recommended for immunotherapeutic interventions at an advanced stage in clinical guidelines. Nevertheless, limited benefits of immunotherapy have prompted investigations into underlying mechanisms, leading to the proposal of metabolic dysregulation‐induced immunoevasion as a crucial contributor. In this study, a significant decrease is found in the abundance of alpha‐ketoglutarate (αKG), a crucial intermediate metabolite in the TCA cycle, which is correlated with higher grades and a worse prognosis in clinical RCC samples. Elevated levels of αKG promote major histocompatibility complex‐I (MHC‐I) antigen processing and presentation, as well as the expression of β2‐microglobulin (B2M). While αKG modulates broad‐spectrum demethylation activities of histone, the transcriptional upregulation of B2M is dependent on the demethylation of H3K4me1 in its promoter region. Furthermore, the combination of αKG supplementation and PD‐1 blockade leads to improved therapeutic efficacy and prolongs survival in murine models when compared to monotherapy. Overall, the findings elucidate the mechanisms of immune evasion in anti‐tumor immunotherapies and suggest a potential combinatorial treatment strategy in RCC.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Department of Urology, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, China.
- Institute of Organ Transplantation, Tongji Hospital, Tongji Medical College, Huazhong University of Science and Technology, Key Laboratory of Organ Transplantation, Ministry of Education, NHC Key Laboratory of Organ Tra…
- Institute of Reproductive Health, Center for Reproductive Medicine, Tongji Medical College, Huazhong University of Science and Technology, Wuhan, 430030, P.R. China.
- Department of Medicine, Division of Hematology/Oncology, Northwestern University Feinberg School of Medicine, Chicago, IL, 60611, USA.
- Department of Molecular Medicine, Beckman Research Institute of City of Hope, Duarte, CA, 91010, USA.
- Fudan University Shanghai Cancer Center & MOE Key Laboratory of Metabolism and Molecular Medicine and Department of Biochemistry and Molecular Biology of School of Basic Medical Sciences, Shanghai Medical College of Fud…
ORCID-Profile: Zhihua Wang
Förderung
- National Natural Science Foundation of China
- Medical Science Data Center of Fudan university
- Fundamental Research Funds for the Central Universities
Zitieren
APA
Li, L., Zeng, X., Chao, Z., Luo, J., Guan, W., Zhang, Q., Ge, Y., Wang, Y., Xiong, Z., Ma, S., Zhou, Q., Zhang, J., Tian, J., Horne, D., Yuh, B., Hu, Z., Wei, G. H., Wang, B., Zhang, X., …, & Wang, Z. (2023). Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma. Advanced Science. https://doi.org/10.1002/advs.202301975
Vancouver
Li L, Zeng X, Chao Z, Luo J, Guan W, Zhang Q, et al. Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma. Advanced Science. 2023. doi:10.1002/advs.202301975
BibTeX
@article{Li2023,
author = {Li, Le and Zeng, Xing and Chao, Zheng and Luo, Jing and Guan, Wei and Zhang, Qiang and Ge, Yue and Wang, Yanan and Xiong, Zezhong and Ma, Sheng and Zhou, Qiang and Zhang, Junbiao and Tian, Jihua and Horne, David and Yuh, Bertram and Hu, Zhiquan and Wei, Gong-Hong and Wang, Baojun and Zhang, Xu and Lan, Peixiang and Wang, Zhihua},
title = {Targeting Alpha‐Ketoglutarate Disruption Overcomes Immunoevasion and Improves PD‐1 Blockade Immunotherapy in Renal Cell Carcinoma},
journal = {Advanced Science},
year = {2023},
doi = {10.1002/advs.202301975}
}
EUVIMED